Effectiveness of pertussis vaccination in pregnancy to prevent hospitalisation in infants aged <2 months and effectiveness of both primary vaccination and mother's vaccination in pregnancy in infants aged 2-11 months

• DOI: 10.1016/j.vaccine.2022.09.054
• Publication Date: 2022-09-29T04:52:34Z
• Authors: Lore Merdrignac; Lesly Acosta; Adele Habington; Manuel Garcìa Cenoz; Elisabetta Pandolfi; Kateřina Fabiánová; Iolanda Jordan; Niam O'Sullivan; Ana Navasués; Alberto E. Tozzi; Jana Zavadilová; Mireia Jané; Suzanne Cotter; Nerea I. Pitillas; Caterina Rizzo; Pavla Křížová; Thomas Hanslik; Carmen Muñoz Almagro; Lucia Pastore; Sabrina Bacci; Alain Moren; Marta Valenciano
• Keywords: Vigilancia hospitalaria; 61; Efectividad de la vacuna; Tos ferina -- Vacunes; Whooping Cough; Hospital surveillance; Pertussis; Vaccine effectiveness; Vaccine in pregnancy; Whooping cough; Mothers; Article; 03 medical and health sciences; 0302 clinical medicine; Pertussis; Pregnancy; Tos ferina; Humans; Vaccine in pregnancy; Vigilància hospitalària; Vaccine effectiveness; Pertussis Vaccine; Vaccines; Whooping cough; PertussisVaccine effectiveness; Efectivitat de la vacuna; Vacuna durant l'embaràs; Hospital surveillance; Vaccination; 3. Good health; Hospitalization; Vacuna en el embarazo; Case-Control Studies; Àrees temàtiques de la UPC::Ciències de la salut::Medicina; Female

PERTINENT is an active hospital-based surveillance system for pertussis in infants. In 2019, four of the six participating European countries recommended vaccination pregnancy. Among infants aged <2 months, we measured vaccine effectiveness (VE) pregnancy; among 2–11 VE pregnancy and primary (PV). From December 2015 to included all <1 year presenting with pertussis-like symptoms. Using a test-negative-design, cases were testing positive Bordetella by PCR or culture. Controls those negative species. Vaccinated mothers who received ≥1 dose PV > 14 days before symptom onset. We excluded unknown maternal status vaccinated ≤14 delivery. calculated pooled as 100 * (1-odds ratio vaccination) adjusted study site, onset date quarters infants’ age group. Of 829 symptoms, 336 (41%) too young PV. For analysis, 75 201 controls. Vaccination was recorded 9 (12%) 92 controls (46%), between 75% [95%CI: 35–91%] 88% 57–96%]. 493 eligible PV, 123 253 Thirty-one 98 both ≥ 1 pregnancy, 74% 33–90] 95% 69–99]; 27 53 only, 68% 27–86] 94% 59–99]. Our findings suggest that reduces incidence only provide significant protection against severe pertussis.